Recent News
April 29,
2022
Zosano Pharma Provides Corporate Update
April 11,
2022
Zosano Pharma Announces Reverse Stock Split Effective Today
At Zosano Pharma, the safety and well-being of our employees and the community remain our highest priority. In response to the spread of COVID-19, we are addressing the issue with the seriousness it deserves.
Live at the Speed of Life
Zosano Pharma is a clinical-stage biopharmaceutical company enabling the systemic administration of therapeutics and other bioactive molecules to patients using our proprietary transdermal microneedle patch system. We have pioneered a novel paradigm for delivering molecules typically administered parenterally, where the inconvenience and pain associated with subcutaneous, intravenous or other complex administrations present barriers to compliance. Our strengths lie in our diverse team of industry veterans with proven drug and device development and significant commercialization experience.
With our proprietary transdermal microneedle patch system, therapeutic blood levels are obtained more rapidly than with oral administration.
Ready. Set. Apply. Three easy steps for administration.
April 29,
2022
Zosano Pharma Provides Corporate Update
April 11,
2022
Zosano Pharma Announces Reverse Stock Split Effective Today
*M207 (zolmitriptan transdermal microneedle system)